Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis

Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis

Summary: Glioblastoma (GBM) is the most common lethal primary brain cancer in adults. Despite treatment regimens including surgical resection, radiotherapy, and temozolomide (TMZ) chemotherapy, growth of residual tumor leads to therapy resistance and death. At recurrence, a quarter to a third of all...

Full description

Bibliographic Details
Main Authors: I-Li Tan, Alexendar R. Perez, Rachel J. Lew, Xiaoyu Sun, Alisha Baldwin, Yong K. Zhu, Mihir M. Shah, Mitchel S. Berger, Jennifer A. Doudna, Christof Fellmann
Format: Article
Language:English
Published: Elsevier 2023-11-01
Series:Cell Reports
Subjects:
CP: Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124723013517

Similar Items

Similar Items